Seeking Alpha Author Ian Bezek joins Cheddar to discuss why Molson Coors stock is down 20% this year. As other alcohol companies are surging at least 30%, Bezek explores why Molson Coors fell behind.
He believes the first reason may be that it's got a
"merger hangover." Molson Coors made a huge purchase last year, buying the MillerCoors assets that Anheuser-Busch had to sell for anti-trust reasons as part of its merger with SABMiller. He believes eventually this merger will positively effect Molson Coors sales, but it hasn't panned out yet.
Plus, Bezek talks about Molson Coors' stronghold on the craft beer industry. It's the #2 brewer in the U.S. and the UK and because of that has strong potential to turn around in 2018.
YouTube will offer creators a way to rejoin the streaming platform if they were banned for violating COVID-19 and election misinformation policies that are no longer in effect.
Lukas Alpert of MarketWatch explores how networks, brands, and ad buyers absorb the shockwaves when late‑night show hosts are suddenly cut — and brought back.
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
